The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by Piper Sandler on March 14, 2025. The analyst firm set a price target for $6.00 expecting AKBA to rise to within 12 ...

Get the latest news on Akebia Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Akebia Therapeutics performance ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Call Transcript March 13, 2025 Akebia Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.05.

Good day, and welcome to Akebia's fourth-quarter 2024 financial results call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to Mercedes ...

CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.

AKEBIA THERAPEUTICS ($AKBA) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.10 per share, missing estimates of -$0.08 ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a fourth-quarter loss of $22.8 million, after reporting a profit in the same period a year ...